Weiss Jana M, Andersson Patrik L, Lamoree Marja H, Leonards Pim E G, van Leeuwen Stefan P J, Hamers Timo
Institute for Environmental Studies, Department of Chemistry and Biology, VU University, 1081 HV Amsterdam, The Netherlands.
Toxicol Sci. 2009 Jun;109(2):206-16. doi: 10.1093/toxsci/kfp055. Epub 2009 Mar 17.
Due to their unique surfactant properties, poly- and perfluorinated compounds (PFCs) have been extensively used and can be found all over the environment. Concern about their environmental fate and toxicological properties has initiated several research projects. In the present study, we investigated if PFCs can compete with thyroxine (T(4), i.e., the transport form of thyroid hormone) for binding to the human thyroid hormone transport protein transthyretin (TTR). Such competitive capacity may lead to decreased thyroid hormone levels as previously reported for animals exposed to PFCs. Twenty-four PFCs, together with 6 structurally similar natural fatty acids, were tested for binding capacity in a radioligand-binding assay. The binding potency decreased in the order: perfluorohexane sulfonate > perfluorooctane sulfonate/perfluorooctanoic acid > perfluoroheptanoic acid > sodium perfluoro-1-octanesulfinate > perfluorononanoic acid, with TTR binding potencies 12.5-50 times lower than the natural ligand T(4). Some lower molecular weight compounds with structural similarity to these PFCs were > 100 times less potent than T(4). Simple descriptors based on the two-dimensional molecular structures of the compounds were used to visualize the chemical variation and to model the structure-activity relationship for the competitive potencies of the TTR-binding compounds. The models indicated the dependence on molecular size and functional groups but demanded a more detailed description of the chemical properties and data for validation and further quantitative structure-activity relationship (QSAR) development. Competitive binding of PFCs to TTR, as observed for human TTR in the present study, may explain altered thyroid hormone levels described for PFC-exposed rats and monkeys. Median human blood levels of the most potent TTR-binding PFCs are one to two orders of magnitude lower than concentration at 50% inhibition (IC(50)) values determined in the present study. In addition, this study contributes to the understanding of the bioaccumulation of PFCs in man and possibly in other wildlife species.
由于其独特的表面活性剂特性,多氟和全氟化合物(PFCs)已被广泛使用,并且在整个环境中都能找到。对其环境归宿和毒理学特性的关注引发了多个研究项目。在本研究中,我们调查了PFCs是否能与甲状腺素(T4,即甲状腺激素的转运形式)竞争结合人类甲状腺激素转运蛋白转甲状腺素蛋白(TTR)。这种竞争能力可能会导致甲状腺激素水平降低,正如之前报道的暴露于PFCs的动物那样。在放射性配体结合试验中测试了24种PFCs以及6种结构相似的天然脂肪酸的结合能力。结合效力按以下顺序降低:全氟己烷磺酸盐>全氟辛烷磺酸盐/全氟辛酸>全氟庚酸>全氟-1-辛烷磺酸钠>全氟壬酸,其与TTR的结合效力比天然配体T4低12.5至50倍。一些与这些PFCs结构相似的低分子量化合物的效力比T4低100倍以上。基于化合物二维分子结构的简单描述符用于可视化化学变化,并为TTR结合化合物的竞争效力建立结构-活性关系模型。这些模型表明了对分子大小和官能团的依赖性,但需要对化学性质进行更详细的描述以及数据来进行验证和进一步发展定量构效关系(QSAR)。如本研究中对人类TTR所观察到的,PFCs与TTR的竞争性结合可能解释了暴露于PFCs的大鼠和猴子甲状腺激素水平的改变。人类血液中最有效的TTR结合PFCs的中位数水平比本研究中测定的50%抑制浓度(IC50)值低一到两个数量级。此外,本研究有助于理解PFCs在人类以及可能在其他野生动物物种中的生物累积情况。